GSK.L
Latest Trade
1,344.80GBpChange
1.00(+0.07%)Volume
5,743,990Today's Range
-
1,358.2052 Week Range
-
1,857.00As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay
Previous Close | 1,343.80 |
|---|---|
Open | 1,339.80 |
Volume | 5,743,990 |
3M AVG Volume | 131.29 |
Today's High | 1,358.20 |
Today's Low | 1,334.80 |
52 Week High | 1,857.00 |
52 Week Low | 1,324.40 |
Shares Out (MIL) | 5,017.38 |
Market Cap (MIL) | 67,423.49 |
Forward P/E | -- |
Dividend (Yield %) | 7.37 |
AnaptysBio And GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration
GSK Says FDA Approves Nucala As Biologic Treatment For Hypereosinophilic Syndrome
BRIEF-Sanofi, GSK Sign Agreements With Canada For Up To 72 Million Doses Of Adjuvanted COVID-19 Vaccine
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
Industry
Biotechnology & Drugs
Contact Info
G S K House, 980 Great West Road
TW8 9GS
United Kingdom
+44.20.80475000
https://www.gsk.com/Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 10.11 |
|---|---|
Price To Sales (TTM) | 1.93 |
Price To Book (MRQ) | 4.90 |
Price To Cash Flow (TTM) | 8.49 |
Total Debt To Equity (MRQ) | 233.13 |
LT Debt To Equity (MRQ) | 189.26 |
Return on Investment (TTM) | 15.87 |
Return on Equity (TTM) | 9.92 |
GlaxoSmithKline Plc said an injection of its cabotegravir drug given every two months, in combination with Johnson & Johnson's rilpivirine, was recommended for approval to treat HIV infections by a panel of the European health regulator.
GlaxoSmithKline Plc said on Friday an injection of its cabotegravir drug given every two months along with Johnson & Johnson's rilpivirine was recommended for approval to treat HIV infections by a panel of the European health regulator.
GlaxoSmithKline <GSK.L> and partner Vir Biotechnology <VIR.O> will expand their trial of an experimental antibody to treat COVID-19 after initial use by a group of volunteers did not raise any safety concerns.
GlaxoSmithKline and partner Vir Biotechnology will expand their trial of an experimental antibody to treat COVID-19 after initial use by a group of volunteers did not raise any safety concerns.
A federal appeals court on Friday reinstated a 2017 jury verdict ordering Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc $235.5 million (£181.6 million) for selling a generic version of Glaxo's heart drug Coreg.
GlaxoSmithKline Plc <GSK.L> executive Thomas Breuer said on Tuesday he has "reservations" against human challenge trials as a tool for determining the effectiveness of COVID-19 vaccine candidates without a therapy for the infection.
An experimental coronavirus vaccine developed by China's Clover Biopharmaceuticals appeared to be safe and able to trigger immune responses in animal tests, researchers have said.
The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi <SASY.PA> and GSK <GSK.L> in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms.
French drugmaker Sanofi <SASY.PA> and Britain's GlaxoSmithKline <GSK.L> said they had started a clinical trial of their protein-based COVID-19 vaccine candidate, and aimed to reach the final testing stage by December.
GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.
The U.S. Food and Drug Administration on Wednesday approved GlaxoSmithKline's <GSK.L> experimental treatment for a common form of blood cancer.
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.
Sanofi SA <SASY.PA> and GlaxoSmithKline Plc <GSK.L> on Friday said they are in advanced discussions with the European Commission to supply up to 300 million doses of the drugmakers's experimental COVID-19 vaccine.
As drugmakers race to develop vaccines and therapies for the novel coronavirus, the United States is rushing to secure access to them. The U.S. government has agreed to invest more than $7 billion in vaccines and has funded more than 30 projects, including for diagnostics...
The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drug makers' testing and manufacturing, the companies said on Friday.
Britain has signed a deal for up to 60 million doses of a potential coronavirus vaccine being developed by Sanofi and GlaxoSmithKline (GSK), it said on Wednesday, its latest such arrangement as the race to tame the pandemic heats up.
* GSK - CONTINUE TO BELIEVE THAT MULTIPLE OPTIONS WILL BE NEEDED TO PREVENT AND TREAT COVID-19
Britain on Wednesday said it had signed a supply deal for up to 60 million doses of a possible COVID-19 vaccine being developed by Sanofi and GlaxoSmithKline, the fourth such deal it has struck.
A panel of the European Medicines Agency (EMA) on Friday has recommended approving GlaxoSmithKline's <GSK.L> experimental treatment for a common form of blood cancer, days after a similar nod from a U.S. Food and Drug Administration panel.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.